受益于丰富的创新药管线储备,多家龙头制药企业实现了多个创新药的海外BD合作,并且预期出海授权将成为可持续的盈利来源。编辑|白鹿作者 | 于晓明执业证书编号:A0680622030012特别提示通过本公众号发布的观点和信息仅供陕西巨丰投资资讯有限责任公司(下称“巨丰投顾”)客户中符合《证券期货投资者适当性管理办法》规定的特定客户参考。因本公众号暂时无法设置访问限制,若您并非巨丰投顾客户,为控制投资...
Source Link受益于丰富的创新药管线储备,多家龙头制药企业实现了多个创新药的海外BD合作,并且预期出海授权将成为可持续的盈利来源。编辑|白鹿作者 | 于晓明执业证书编号:A0680622030012特别提示通过本公众号发布的观点和信息仅供陕西巨丰投资资讯有限责任公司(下称“巨丰投顾”)客户中符合《证券期货投资者适当性管理办法》规定的特定客户参考。因本公众号暂时无法设置访问限制,若您并非巨丰投顾客户,为控制投资...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.